Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $31.20 in the last session, up 1.18% from day before closing price of $30.84. In other words, the price has increased by $1.18 from its previous closing price. On the day, 0.7 million shares were traded. RNA stock price reached its highest trading level at $31.53 during the session, while it also had its lowest trading level at $30.77.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $70.
On March 12, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $72.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’25 when Gallagher Kathleen P. sold 5,875 shares for $27.83 per share. The transaction valued at 163,486 led to the insider holds 50,554 shares of the business.
Hughes Steven George sold 9,578 shares of RNA for $297,491 on Mar 20 ’25. The Chief Medical Officer now owns 72,850 shares after completing the transaction at $31.06 per share. On Mar 20 ’25, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 31,540 shares for $31.06 each. As a result, the insider received 979,563 and left with 305,871 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3751215360 and an Enterprise Value of 2256528896. For the stock, the TTM Price-to-Sale (P/S) ratio is 344.15 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 207.078 whereas that against EBITDA is -5.999.
Stock Price History:
The Beta on a monthly basis for RNA is 1.00, which has changed by 0.29320347 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 5.13%, while the 200-Day Moving Average is calculated to be -17.51%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.52M shares per day over the past 3-months and 1318840 shares per day over the past 10 days. A total of 119.89M shares are outstanding, with a floating share count of 111.14M. Insiders hold about 7.55% of the company’s shares, while institutions hold 104.10% stake in the company. Shares short for RNA as of 1744675200 were 15483940 with a Short Ratio of 10.18, compared to 1741910400 on 16128099. Therefore, it implies a Short% of Shares Outstanding of 15483940 and a Short% of Float of 15.86.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Avidity Biosciences Inc (RNA) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $-0.92, with high estimates of $-0.57 and low estimates of $-1.18.
Analysts are recommending an EPS of between $-2.38 and $-4.99 for the fiscal current year, implying an average EPS of $-3.82. EPS for the following year is $-4.3, with 13.0 analysts recommending between $-2.34 and $-5.77.
